Calithera Biosciences Inc. Daily Stock Analysis

Daily Stock Analysis, CALA, Calithera Biosciences Inc, priceseries

Calithera Biosciences Inc. Daily Stock Analysis
Stock Information
Open
0.44
Close
0.43
High
0.44
Low
0.42
Previous Close
0.45
Daily Price Gain
-0.02
YTD High
0.74
YTD High Date
Jan 31, 2022
YTD Low
0.39
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.25
YTD Gain
-36.58%
52 Week High
2.97
52 Week High Date
Mar 16, 2021
52 Week Low
0.39
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-2.26
52 Week Gain
-84.01%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2017
3.60
Jan 19. 2017
4.26
11 Trading Days
18.45%
Link
LONG
Feb 24. 2017
8.95
Mar 17. 2017
12.46
15 Trading Days
39.19%
Link
LONG
May 9. 2017
11.30
May 31. 2017
15.55
15 Trading Days
37.62%
Link
LONG
Jul 3. 2017
15.75
Jul 17. 2017
17.95
9 Trading Days
13.95%
Link
LONG
Oct 4. 2017
15.85
Oct 19. 2017
17.24
11 Trading Days
8.78%
Link
LONG
Aug 24. 2018
4.75
Sep 6. 2018
5.02
8 Trading Days
5.64%
Link
LONG
Feb 8. 2019
4.86
Mar 5. 2019
5.62
16 Trading Days
15.57%
Link
LONG
Mar 8. 2019
5.75
Mar 25. 2019
6.40
11 Trading Days
11.34%
Link
LONG
Oct 31. 2019
2.88
Nov 11. 2019
3.16
7 Trading Days
9.86%
Link
LONG
Dec 20. 2019
4.79
Jan 2. 2020
5.33
7 Trading Days
11.24%
Link
LONG
Jan 9. 2020
5.87
Jan 24. 2020
6.52
10 Trading Days
11.13%
Link
LONG
Apr 3. 2020
4.42
Apr 20. 2020
6.27
10 Trading Days
41.77%
Link
LONG
Oct 5. 2020
3.61
Oct 20. 2020
3.82
11 Trading Days
5.86%
Link
LONG
Nov 12. 2020
4.27
Dec 2. 2020
4.68
13 Trading Days
9.70%
Link
Company Information
Stock Symbol
CALA
Exchange
NasdaqGS
Company URL
http://www.calithera.com
Company Phone
650-870-1000
CEO
Susan M. Molineaux
Headquarters
California
Business Address
343 OYSTER POINT BLVD #200, SOUTH SAN FRANCISCO, CA 94080
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001496671
About

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company, which focuses on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Description

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors. In addition, it has clinical trial collaboration with Bristol-Myers Squibb Company to evaluate Opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma. The company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of CB-1158, a small molecule arginase inhibitor for the treatment of hematology and oncology. Calithera Biosciences, Inc. was founded in 2010 and is headquartered in South San Francisco, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading